mRNA-1345

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Severe Acute Respiratory SyndromeRespiratory Syncytial VirusRSV

69 competitors in Severe Acute Respiratory Syndrome

#DrugCompanyPhaseTrials

1

Nicorette

Pfizer

Approved

—2

Jakafi

Incyte

Approved

—3

Luvox

SSolvay Pharmaceuticals

Approved

—4

Decadron

AAspen Global Incorporated

Approved

—5

Ketalar

AAultman Health Foundation

Approved

—6

Methylthioninium Chloride

PProvepharm SAS

Approved

—7

Fluzone

Sanofi

Phase 3

—8

Actemra

Roche

Phase 3

—9

Simdax

Orion Corporation, Orion Pharma

Phase 3

—10

Heparin Sodium

Haisco Pharmaceutical Group Co., Ltd.

Approved

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus (RSV)7 trials

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Active, not recruiting·Moderna·Phase 3·NCT07117487·507 enrolled

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

Completed·Moderna·Phase 2/3·NCT05127434·36,814 enrolled

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Completed·Moderna··NCT05572658·10,994 enrolled

Show 4 more trials

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Completed·Moderna·Phase 3·NCT06060457·1,900 enrolled

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Completed·Moderna·Phase 3·NCT05330975·3,317 enrolled

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Active, not recruiting·Moderna·Phase 3·NCT06067230·1,153 enrolled

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Completed·Moderna·Phase 1·NCT04528719·651 enrolled

Respiratory Syncytial Virus3 trials

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Active, not recruiting·Moderna·Phase 2·NCT06143046·360 enrolled

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Completed·Moderna·Phase 2·NCT06097299·346 enrolled

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active, not recruiting·Moderna·Phase 1·NCT05743881·186 enrolled

Immunogenicity1 trial

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Completed·Moderna·Phase 2·NCT05606965·172 enrolled

mRNA Vaccine1 trial

A Study of Modified mRNA Vaccines in Healthy Adults

Completed·Moderna·Phase 1·NCT05397223·308 enrolled

Severe Acute Respiratory Syndrome1 trial

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Completed·Moderna·Phase 1·NCT05585632·392 enrolled

Details

Drug Info

Related News